Company intelligence / Profile preview

DreamTec

Kwai Chung, Kowloon, Hong Kongdreamtec.hk ↗
Ownership
Public · A192650
Development stage
Other
01

Overview

DreamTec has developed a novel oral COVID‑19 vaccine using genetically engineered Bacillus subtilis spores displaying the SARS-CoV‑2 spike protein receptor-binding domain. Pilot studies in healthy volunteers showed increased neutralizing antibody levels after administration. Preclinical animal data indicated no alarming side effects and induction of IgG/IgM antibodies. The product aims to be stable at room temperature for up to six months and easy to administer orally; Phase I trials are planned or imminent as of the latest reports.

Therapeutic areas
OtherInfectious Diseases
Modalities
Recombinant proteinRNA therapyStem cell therapyExosome-based therapyMicrobial therapy3D bioprinting
Industry
Biotech
02

Drug pipeline

2 assets

Bacillus subtilis spore extract

Unknown

1 more asset in the full pipeline.

03

Partnerships

Chinese University of Hong KongHong Kong Metropolitan University
04

Financials

Market cap
$29.3B
Total revenue
$6.5B
Enterprise value
$45.1B

Beyond the preview

Go deeper on DreamTec.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DreamTec.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call